Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-cash Items (2016 - 2018)

Sangamo Therapeutics has reported Non-cash Items over the past 7 years, most recently at $3.7 million for Q4 2018.

  • Quarterly results put Non-cash Items at $3.7 million for Q4 2018, down 94.84% from a year ago — trailing twelve months through Dec 2018 was $3.7 million (down 94.84% YoY), and the annual figure for FY2018 was $3.7 million, down 94.84%.
  • Non-cash Items for Q4 2018 was $3.7 million at Sangamo Therapeutics, down from $71.7 million in the prior quarter.
  • Over the last five years, Non-cash Items for SGMO hit a ceiling of $71.7 million in Q4 2017 and a floor of $3.7 million in Q4 2018.
  • Median Non-cash Items over the past 5 years was $5.0 million (2015), compared with a mean of $18.3 million.
  • Biggest five-year swings in Non-cash Items: soared 1087.46% in 2017 and later tumbled 94.84% in 2018.
  • Sangamo Therapeutics' Non-cash Items stood at $4.9 million in 2014, then increased by 0.42% to $5.0 million in 2015, then rose by 21.89% to $6.0 million in 2016, then soared by 1087.46% to $71.7 million in 2017, then tumbled by 94.84% to $3.7 million in 2018.
  • The last three reported values for Non-cash Items were $3.7 million (Q4 2018), $71.7 million (Q4 2017), and $6.0 million (Q4 2016) per Business Quant data.